Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Return on Capital Employed (2019 - 2025)

Serina Therapeutics (SER) has disclosed Return on Capital Employed for 7 consecutive years, with 3.93% as the latest value for Q4 2025.

  • Quarterly Return on Capital Employed fell 31.0% to 3.93% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 3.93% through Dec 2025, down 31.0% year-over-year, with the annual reading at 7.34% for FY2025, 423.0% down from the prior year.
  • Return on Capital Employed hit 3.93% in Q4 2025 for Serina Therapeutics, up from 12.38% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 24.01% in Q1 2021 to a low of 12.38% in Q3 2025.
  • Historically, Return on Capital Employed has averaged 0.65% across 5 years, with a median of 1.01% in 2024.
  • Biggest YoY gain for Return on Capital Employed was 5753bps in 2021; the steepest drop was -2601bps in 2021.
  • Year by year, Return on Capital Employed stood at 1.28% in 2021, then dropped by -27bps to 0.94% in 2022, then plummeted by -136bps to 0.34% in 2023, then crashed by -961bps to 3.62% in 2024, then fell by -9bps to 3.93% in 2025.
  • Business Quant data shows Return on Capital Employed for SER at 3.93% in Q4 2025, 12.38% in Q3 2025, and 5.21% in Q2 2025.